In vivo, LOXL2 inhibitor can reduce D‐gal‐induced skeletal muscle fibrosis, inhibit oxidative stress, promote the increase of skeletal muscle mass and strength which plays a protective role in sarcopenia. Here, LOXL2 is linked to sarcopenia.